2 years ago

Cytomos Secures £4 Million to Accelerate Cell Analysis Technology

  • Cytomos, a UK-based life science company, has secured £4 million in funding

  • The round was led by existing investor Archangels with participation from Old College Capital, Scottish Enterprise and new investor British Business Bank

  • Cytomos has developed a proprietary technology platform called Cytomos Dielectric Spectroscopy (CDS) that analyzes cells and enables faster development and reduced costs for novel therapies in the biopharma industry

  • The company intends to use the funds to scale up market-testing of its technology platform and target commercialization in 2024.

      • ProblemHealthcare

      "Bringing novel therapies to market takes a long time and is expensive. Biopharma companies need to be able to make decisions earlier in the process to save time and money."

      Solution

      "Cytomos has developed a new technology called CDS (Cytomos Dielectric Spectroscopy) which allows biopharma companies to analyse cells more quickly and accurately, helping them make decisions earlier in the development process."

      Covered on